LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.840-2.940 for the period, compared to the consensus earnings per share estimate of 3.000. The company issued revenue guidance of $274.3 million-$278.3 million, compared to the consensus revenue estimate of $279.9 million. LeMaitre Vascular also updated its Q3 2026 guidance to 0.660-0.710 EPS.

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $2.17 during mid-day trading on Tuesday, hitting $105.78. 405,320 shares of the stock were exchanged, compared to its average volume of 255,427. LeMaitre Vascular has a 52-week low of $79.39 and a 52-week high of $118.01. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. The company has a market cap of $2.42 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.81 and a beta of 0.52. The firm has a fifty day moving average of $97.27 and a 200 day moving average of $99.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The business had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. Research analysts anticipate that LeMaitre Vascular will post 3 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on LMAT shares. Wells Fargo & Company upped their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Insider Activity

In other news, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 54,453 shares of company stock worth $5,906,174 over the last quarter. 7.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently modified their holdings of LMAT. Mercer Global Advisors Inc. ADV boosted its position in LeMaitre Vascular by 11.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after acquiring an additional 371 shares during the last quarter. NewEdge Advisors LLC raised its holdings in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares during the last quarter. Empowered Funds LLC purchased a new position in LeMaitre Vascular in the 4th quarter worth approximately $289,000. nVerses Capital LLC purchased a new position in LeMaitre Vascular in the 4th quarter worth approximately $234,000. Finally, Voloridge Investment Management LLC boosted its holdings in shares of LeMaitre Vascular by 70.0% during the 4th quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after purchasing an additional 25,901 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.